{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:15:25Z","timestamp":1789992925399,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sparsentan, a dual endothelin type A and angiotensin II type 1 receptor antagonist, has demonstrated antiproteinuric efficacy in randomized trials of IgA nephropathy (IgAN). However, real-world data on treatment response and predictors remain limited. We evaluated longitudinal proteinuria response, kidney function trajectories, and predictors of treatment response over the first year of sparsentan therapy in routine practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center observational study, 38 adults with biopsy-proven IgAN were evaluated at baseline, 3, 6, 9, and 12 months after sparsentan initiation. Predictors of response, defined as\u00a0\u226550% proteinuria reduction with\u00a0\u226415% decline in estimated glomerular filtration rate (eGFR), were evaluated at the 9-month landmark analysis using logistic regression. Longitudinal proteinuria and eGFR trajectories were analyzed using linear mixed models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sparsentan was associated with sustained proteinuria reduction across patient subgroups. In mixed-effects models, proteinuria declined by \u223c8% per month, while the annualized eGFR slope was\u00a0\u22122.5 ml\/min\/1.73 m2\/year. At the 9-month landmark analysis, baseline hematuria [odds ratio (OR) 10.00; 95% confidence interval (CI) 1.28\u201378.12; P\u00a0=\u00a0.028] and higher systolic blood pressure (sBP) (OR 4.30; 95% CI 1.02\u201318.10; P\u00a0=\u00a0.047) were associated with higher odds of response. Sparsentan was generally well tolerated, with discontinuation in 10.5% of patients, including two cases of reversible liver enzyme elevation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In routine practice, sparsentan was associated with sustained antiproteinuric effects with relatively stable kidney function trajectories despite advanced baseline disease. Exploratory analysis identified baseline hematuria and sBP as potential markers of treatment response; however, these findings require validation in larger prospective cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag291","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:11:42Z","timestamp":1788181902000},"source":"Crossref","is-referenced-by-count":0,"title":["Predictors of response and long-term tolerability of sparsentan in a real-world IgA nephropathy cohort"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6104-2891","authenticated-orcid":false,"given":"Anila","family":"Cara","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55901 ,","place":["USA"]},{"name":"Renal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J","family":"Vargas-Brochero","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55901 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristi\u00e1n","family":"Juanet","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55901 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9922-7829","authenticated-orcid":false,"given":"Gian Marco","family":"Berti","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55901 ,","place":["USA"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum \u2013 University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilario","family":"Russo","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55901 ,","place":["USA"]},{"name":"Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C","family":"Fervenza","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55901 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Zand","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55901 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026092104314642100_bib1","doi-asserted-by":"publisher","first-page":"sfaf324","DOI":"10.1093\/ckj\/sfaf324","article-title":"The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective","volume":"18","author":"Stamellou","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026092104314642100_bib2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026092104314642100_bib3","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026092104314642100_bib4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.ajkd.2012.02.326","article-title":"Risk stratification of patients with IgA nephropathy","volume":"59","author":"Barbour","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026092104314642100_bib5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026092104314642100_bib6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40620-023-01833-3","article-title":"Points of view in nephrology: personalized management of IgA nephropathy, beyond KDIGO","volume":"37","author":"Trimarchi","year":"2024","journal-title":"J Nephrol"},{"key":"2026092104314642100_bib7","doi-asserted-by":"publisher","first-page":"sfag003","DOI":"10.1093\/ckj\/sfag003","article-title":"Microscopic hematuria in IgA nephropathy: a biomarker of disease activity","volume":"19","author":"Floege","year":"2026","journal-title":"Clin Kidney J"},{"key":"2026092104314642100_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El\u00a0Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026092104314642100_bib9","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2026092104314642100_bib10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2215\/CJN.0000000961","article-title":"Association between complete proteinuria remission and kidney function in the phase 3 PROTECT trial of sparsentan in IgA nephropathy","volume":"21","author":"Heerspink","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026092104314642100_bib11","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2026092104314642100_bib12","doi-asserted-by":"publisher","first-page":"11151","DOI":"10.1038\/s41598-020-68087-y","article-title":"Validation of the revised Oxford classification for IgA nephropathy considering treatment with corticosteroids\/immunosuppressors","volume":"10","author":"Moriyama","year":"2020","journal-title":"Sci Rep"},{"key":"2026092104314642100_bib13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.ajkd.2013.04.021","article-title":"Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis","volume":"62","author":"Lv","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026092104314642100_bib14","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.ekir.2024.03.032","article-title":"The efficacy and safety of reduced-dose oral methylprednisolone in high-risk immunoglobulin A nephropathy","volume":"9","author":"Kim","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026092104314642100_bib15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ekir.2023.10.015","article-title":"Mycophenolate mofetil and steroid for treatment of patients with IgA nephropathy","volume":"9","author":"Miao","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026092104314642100_bib16","doi-asserted-by":"publisher","first-page":"1515723","DOI":"10.3389\/fmed.2025.1515723","article-title":"Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med"},{"key":"2026092104314642100_bib17","doi-asserted-by":"publisher","first-page":"ii19","DOI":"10.1093\/ckj\/sfad232","article-title":"Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients","volume":"16","author":"Zand","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026092104314642100_bib18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.kint.2016.09.029","article-title":"Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy","volume":"91","author":"Bellur","year":"2017","journal-title":"Kidney Int"},{"key":"2026092104314642100_bib19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"2026092104314642100_bib20","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae394","article-title":"First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors","volume":"18","author":"Schanz","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026092104314642100_bib21","doi-asserted-by":"publisher","first-page":"1673799","DOI":"10.3389\/fneph.2025.1673799","article-title":"Case report: maximizing the anti-proteinuric response: a multicenter real-world sparsentan case series in IgA disorders","volume":"5","author":"Ray","year":"2025","journal-title":"Front Nephrol"},{"key":"2026092104314642100_bib22","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"2026092104314642100_bib23","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1093\/ndt\/gfaf084","article-title":"CKD progression, kidney failure, and mortality among US patients with IgA nephropathy","volume":"40","author":"Sim","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026092104314642100_bib24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of IgA nephropathy: a cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026092104314642100_bib25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12882-025-03958-y","article-title":"Lifetime progression of IgA nephropathy: a retrospective cohort study with extended long-term follow-up","volume":"26","author":"Rivedal","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026092104314642100_bib26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.kint.2019.05.007","article-title":"Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells","volume":"96","author":"Ebefors","year":"2019","journal-title":"Kidney Int"},{"key":"2026092104314642100_bib27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.semnephrol.2015.02.005","article-title":"Endothelin and the glomerulus in chronic kidney disease","volume":"35","author":"Barton","year":"2015","journal-title":"Semin Nephrol"},{"key":"2026092104314642100_bib28","doi-asserted-by":"publisher","first-page":"e177775","DOI":"10.1172\/jci.insight.177775","article-title":"Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS","volume":"9","author":"Gyarmati","year":"2024","journal-title":"JCI Insight"},{"key":"2026092104314642100_bib29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/1744666X.2024.2319132","article-title":"Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy","volume":"20","author":"Trachtman","year":"2024","journal-title":"Exp Rev Clin Immunol"},{"key":"2026092104314642100_bib30","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"KDIGO 2024.","year":"2024","journal-title":"Kidney Int"},{"key":"2026092104314642100_bib31","doi-asserted-by":"publisher","first-page":"F862","DOI":"10.1152\/ajprenal.00253.2023","article-title":"Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy","volume":"326","author":"Reily","year":"2024","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026092104314642100_bib32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1042\/CS20240249","article-title":"Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease","volume":"138","author":"Kohan","year":"2024","journal-title":"Clin Sci"},{"key":"2026092104314642100_bib33","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2025rz3t03tr","article-title":"Effect of sparsentan (SPAR) on proteinuria and urinary inflammatory and profibrotic biomarkers by baseline proteinuria strata in SPARTAN study participants with IgAN","volume":"36","author":"Cheung","year":"2025","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag291\/70881956\/sfag291.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag291\/70881956\/sfag291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag291\/70881956\/sfag291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:47:24Z","timestamp":1789991244000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag291\/8776682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag291","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,31]]},"article-number":"sfag291"}}